TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

January 5 Deadline Alert: Law Offices of Howard G. Smith Reminds Teva Pharmaceutical Industries Limited Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) securities between February 10, 2014 and November 3, 2016, inclusive (the “Class Period”). Teva investors have until January 5, 2017 to file a lead plaintiff motion.

On November 3, 2016, Bloomberg published the article “U.S. Charges in Generic-Drug Probe to Be Filed by Year End” which discussed the Department of Justice’s two year investigation of suspected price collusion by several pharmaceutical companies, including Teva, which will likely result in prosecutors filing criminal charges by the end of the year.

The complaint filed in this lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva and several of its pharmaceutical industry peers colluded to fix generic drug prices; (2) the foregoing conduct constituted a violation of federal antitrust laws; (3) consequently, Teva’s revenues during the Class Period were in part the result of illegal conduct; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

If you purchased Teva shares, you may move the Court no later than January 5, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
30/12/2016

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

Teva and Blackstone Life Sciences Announce $400 Million Strategic Grow...

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD)Agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutic...

Teva Pharmaceutical Industries Ltd: 1 director

A director at Teva Pharmaceutical Industries Ltd sold 345,810 shares at 33.645USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

 PRESS RELEASE

Teva to Present at the Upcoming Investor Conferences in March

Teva to Present at the Upcoming Investor Conferences in March PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare ConferenceTuesday, Mar...

 PRESS RELEASE

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

 PRESS RELEASE

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch